Stock Analysis
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
Sarepta Therapeutics, Inc. (SRPT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Sarepta Therapeutics, Inc. (SRPT) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 67/100. Risk is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SRPT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $20.45 |
| AIQ Score | 55/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $2.25B |
| P/E Ratio | -35.55 |
| Forward P/E | — |
| EPS | -$0.05 |
| Revenue TTM | $401.25M |
| Dividend Yield | 0.00% |
| Beta | 0.21 |
| Volume | 1.8M |
| 52-week range | $14.68-$25.32 |
| RSI 14 | 56.85 |
| 50-Day SMA | $18.49 |
| 200-Day SMA | $19.26 |
| Analyst Price Target | $23.33 |
| Next Earnings | Nov 4, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
SRPT
OverviewSRPT Stock Analysis Summary
Sarepta Therapeutics, Inc. (SRPT) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 67/100. Risk resilience is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, SRPT has AIQ Score of 55/100 with Momentum base of 67/100 and fading Risk resilience at 38/100. Wait for component alignment before adding exposure.
Momentum (67/100) leads while Risk resilience (38/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.34% stock move · SRPT classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SRPT Bullish or Bearish Right Now?
SRPT currently has a neutral overall setup. Momentum is the strongest factor at 67/100, while Risk Resilience is weakest at 38/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 67/100.
- - Price is +10.61% above its 50-day SMA.
- - Analyst target implies +14.08% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (25 vs 14).
- - Risk Resilience is weak at 38/100.
Current Consensus
SRPT's Technical Analysis Consensus is currently Buy, with 25 buy, 6 neutral, and 14 sell votes. SRPT's 14-day RSI is 56.85, which places the stock in a constructive momentum range. SRPT's beta is 0.21, indicating lower market sensitivity than the broad market.
What Changed in SRPT?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the SRPT Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SRPT Decision Framework
Public evidence layers, setup checks, and risk context for Sarepta Therapeutics, Inc..
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
Sarepta Therapeutics, Inc. has an AIQ Score of 55/100 in a Neutral regime. Momentum is strongest at 67/100. Beta is 0.21, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SRPT is in a Neutral AIQ regime with score 55/100. |
| Signal Conflict | The primary conflict is that momentum leads at 67/100 while risk lags at 38/100. |
| Factor Evidence | Momentum 67/100 · Value 64/100 · Quality 46/100 · Risk 38/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 67/100.
Momentum is 67/100 and RSI (14) is 56.8.
SRPT is in a Neutral regime at 55/100.
Risk factor is 38/100 with beta 0.21 and annual volatility 81.3%.
Current conflict: momentum leads at 67/100 while risk lags at 38/100.
SRPT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SRPT Fundamentals
SRPT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SRPT Technical Analysis
SRPT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SRPT Stock Catalysts
Track SRPT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SRPT Dividend Analysis
SRPT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SRPT Financial Data
SRPT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SRPT Risk Analysis
SRPT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SRPT Stock News
SRPT stock news, market tone, recent headlines, and catalyst context.
SRPT vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: SRPT · VERA · VRNA · WVE · XNCR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SRPT Current stock | 55/100 | 64/100 | 67/100 | 38/100 | 0.58 | 81.30% | Current |
| VERA Vera Therapeutics | 42/100 | — | 50/100 | 57/100 | 0.84 | 59.41% | SRPT vs VERA |
| VRNA Verona Pharma | 43/100 | 34/100 | — | 54/100 | 1.41 | 41.05% | SRPT vs VRNA |
| WVE Wave Life Sciences | 40/100 | 34/100 | 25/100 | 40/100 | 0.26 | 168.13% | SRPT vs WVE |
| XNCR Xencor | 45/100 | 34/100 | 47/100 | 55/100 | 1.88 | 67.18% | SRPT vs XNCR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SRPT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SRPT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SRPT Stock FAQ
What is SRPT stock price today?
Sarepta Therapeutics, Inc.'s current stock price is $20.45. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SRPT bullish or bearish right now?
SRPT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SRPT's market cap?
SRPT's market cap is $2.25B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SRPT's current P/E ratio?
SRPT's current P/E ratio is -35.55 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SRPT's RSI?
SRPT's 14-day RSI is 56.85 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SRPT above its 50-day and 200-day moving averages?
SRPT is 10.61% from its 50-day SMA and 6.18% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SRPT's next earnings date?
SRPT's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SRPT pay a dividend?
SRPT's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.